Matching articles for "NuvaRing"

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • May 15, 2023;  (Issue 1676)
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also effective...
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also effective in preventing pregnancy. When used alone, barrier and behavioral methods generally have higher failure rates than other methods (see Table 1). Selection of a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80 | Show Full IntroductionHide Full Introduction

Phexxi - A Nonhormonal Contraceptive Gel

   
The Medical Letter on Drugs and Therapeutics • August 24, 2020;  (Issue 1605)
The FDA has approved Phexxi (Evofem), a nonhormonal prescription-only vaginal gel containing lactic acid, citric acid, and potassium bitartrate, for prevention of pregnancy. The gel is intended for...
The FDA has approved Phexxi (Evofem), a nonhormonal prescription-only vaginal gel containing lactic acid, citric acid, and potassium bitartrate, for prevention of pregnancy. The gel is intended for on-demand contraception; it is not effective when used after intercourse. It was previously approved for use as a vaginal lubricant (Amphora), but was never marketed.
Med Lett Drugs Ther. 2020 Aug 24;62(1605):129-32 | Show Full IntroductionHide Full Introduction

Annovera - A New Contraceptive Vaginal Ring

   
The Medical Letter on Drugs and Therapeutics • December 16, 2019;  (Issue 1587)
Annovera (TherapeuticsMD), a contraceptive vaginal ring that releases segesterone acetate, a synthetic progestin, and ethinyl estradiol, was approved by the FDA in 2018 and is now available. It is the first...
Annovera (TherapeuticsMD), a contraceptive vaginal ring that releases segesterone acetate, a synthetic progestin, and ethinyl estradiol, was approved by the FDA in 2018 and is now available. It is the first product to contain segesterone and the second vaginal ring to become available in the US; NuvaRing, which delivers etonogestrel and ethinyl estradiol, was the first. Unlike NuvaRing, which requires use of a new ring each month, the Annovera ring can be used for an entire year, but it must be removed for one week each month.
Med Lett Drugs Ther. 2019 Dec 16;61(1587):197-8 | Show Full IntroductionHide Full Introduction

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • October 8, 2018;  (Issue 1557)
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also highly...
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also highly effective in preventing pregnancy. When used alone, barrier and fertility-based methods generally have higher failure rates than other methods.
Med Lett Drugs Ther. 2018 Oct 8;60(1557):161-8 | Show Full IntroductionHide Full Introduction

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • September 14, 2015;  (Issue 1477)
Implants, intrauterine devices (IUDs), and sterilization are the most effective contraceptive methods available. Pills, patches, rings, and injectables, when used correctly, are also highly effective in...
Implants, intrauterine devices (IUDs), and sterilization are the most effective contraceptive methods available. Pills, patches, rings, and injectables, when used correctly, are also highly effective in preventing pregnancy. Barrier and fertility-based methods have the highest rates of failure.
Med Lett Drugs Ther. 2015 Sep 14;57(1477):127-32 | Show Full IntroductionHide Full Introduction

A New Low-Dose Levonorgestrel-Releasing IUD (Skyla)

   
The Medical Letter on Drugs and Therapeutics • March 18, 2013;  (Issue 1412)
The FDA recently approved Skyla (Bayer), the first new intrauterine device (IUD) in the US in 12 years. It releases levonorgestrel, a synthetic progestin, over a period of 3 years. A table summarizing...
The FDA recently approved Skyla (Bayer), the first new intrauterine device (IUD) in the US in 12 years. It releases levonorgestrel, a synthetic progestin, over a period of 3 years. A table summarizing contraceptive methods available in the US appears on page 22.
Med Lett Drugs Ther. 2013 Mar 18;55(1412):21-2 | Show Full IntroductionHide Full Introduction

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • December 1, 2010;  (Issue 100)
The choice of which contraceptive to use may vary from one stage of reproductive life to another. Intrauterine devices (IUDs), progestin implants and sterilization are the most effective contraceptive methods...
The choice of which contraceptive to use may vary from one stage of reproductive life to another. Intrauterine devices (IUDs), progestin implants and sterilization are the most effective contraceptive methods available to women. Hormonal contraceptives, when used correctly, are also highly effective in preventing pregnancy. Barrier and fertility-based methods have the highest rate of failure.
Treat Guidel Med Lett. 2010 Dec;8(100):89-96 | Show Full IntroductionHide Full Introduction

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • December 1, 2007;  (Issue 64)
Transdermal, transvaginal and intrauterine hormone delivery systems have made highly effective contraceptive products more convenient to use. New oral contraceptive options include regimens with fewer or...
Transdermal, transvaginal and intrauterine hormone delivery systems have made highly effective contraceptive products more convenient to use. New oral contraceptive options include regimens with fewer or shorter hormone-free intervals.
Treat Guidel Med Lett. 2007 Dec;5(64):101-8 | Show Full IntroductionHide Full Introduction

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • August 1, 2004;  (Issue 24)
In recent years, several new contraceptive options have become available in the United States. Novel hormone delivery systems such as transdermal, transvaginal and intrauterine devices have improved the...
In recent years, several new contraceptive options have become available in the United States. Novel hormone delivery systems such as transdermal, transvaginal and intrauterine devices have improved the convenience of highly effective contraceptive products. Like oral contraceptives and most barrier contraceptives, these devices do not protect against sexually transmitted diseases.
Treat Guidel Med Lett. 2004 Aug;2(24):55-62 | Show Full IntroductionHide Full Introduction